Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Gastro-enteropancreatic neuroendocrine tumor × Nivolumab × 90 days × Clear all

Sponsor

Conditions

Melanoma 50 Carcinoma, Non-Small-Cell Lung 40 Carcinoma, Renal Cell 26 Neoplasm Metastasis 19 Lung Neoplasms 18 Squamous Cell Carcinoma of Head and Neck 14 Stomach Neoplasms 13 Colorectal Neoplasms 13 Neoplasms 12 Skin Neoplasms 10 Carcinoma, Hepatocellular 10 Urinary Bladder Neoplasms 9 Carcinoma, Transitional Cell 9 Adenocarcinoma Of Esophagus 9 Carcinoma, Merkel Cell 8 Prostatic Neoplasms 7 Rectal Neoplasms 6 Colonic Neoplasms 6 Uveal Melanoma 5 Small Cell Lung Carcinoma 5 Recurrence 5 Ovarian Neoplasms 5 Glioblastoma 5 Esophageal Neoplasms 5 Breast Neoplasms 5 Brain Neoplasms 5 Turcot syndrome 4 Triple Negative Breast Neoplasms 4 Sarcoma 4 Nasopharyngeal Carcinoma 4

Interventions

lutetium Lu 177 dotatate 3 pasireotide 2 Octreotide 2 lanreotide 1 copper dotatate CU-64 1 abemaciclib 1 Sunitinib 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Lutetium-177 1 Lutetium 1 Everolimus 1 E-7386 1 Cryotherapy 1 Acupuncture Therapy 1 Acupressure 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡